Molecular identification and antifungal susceptibility among clinical isolates of dermatophytes in Shiraz, Iran (2017-2019).
Adolescent
Adult
Antifungal Agents
/ pharmacology
Arthrodermataceae
/ classification
Child
Child, Preschool
Cross-Sectional Studies
DNA, Ribosomal Spacer
/ genetics
Dermatomycoses
/ drug therapy
Female
Humans
Infant
Iran
/ epidemiology
Male
Microbial Sensitivity Tests
Middle Aged
Quality of Life
Young Adult
antifungal susceptibility testing
dermatophytes
internal transcribed spacer
superficial mycoses
tinea
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
06
10
2020
revised:
28
11
2020
accepted:
02
12
2020
pubmed:
10
12
2020
medline:
3
9
2021
entrez:
9
12
2020
Statut:
ppublish
Résumé
Dermatophytosis is a common superficial mycotic infection affecting individual's quality of life worldwide. The present study aimed to perform species-level identification and evaluate the antifungal susceptibility patterns of dermatophytes isolated in Shiraz, Iran. This cross-sectional study was conducted on clinical samples collected during 2017-2019 from 307 patients suspected of having dermatophytosis. The isolates were identified by direct microscopy, culture and internal transcribed spacer ribosomal DNA sequencing, and their antifungal susceptibility patterns were determined by the microdilution method. Among 307 patients, dermatophytosis was diagnosed by microscopy in 190 (61.8%) subjects and confirmed in 130 (42.3%) cases by both microscopy and culture. It was found out tinea pedis was the most common clinical manifestation, and Trichophyton mentagrophytes was the most prevalent species (28.4%), followed by T tonsurans (23.8%), Microsporum canis (11.5%), T interdigitale (10%), T verrucosum (6.9%), T rubrum (6.9%), T benhamiae (4.6%), T violaceum (3%), T simii (3%), Epidermophyton floccosum (0.7%) and M ferrugineum (0.7%). Moreover, it was revealed that luliconazole with a geometric mean (GM) minimum inhibitory concentration (MIC) of 0.03 μg ml
Substances chimiques
Antifungal Agents
0
DNA, Ribosomal Spacer
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-393Subventions
Organisme : Vice-Chancellor for Research of Shiraz University of Medical Sciences
ID : 16463
Informations de copyright
© 2020 Wiley-VCH GmbH.
Références
De Hoog GS, Dukik K, Monod M, et al. Toward a novel multilocus phylogenetic taxonomy for the dermatophytes. Mycopathologia. 2017;182:5-31.
Bhatia VK, Sharma PC. Epidemiological studies on dermatophytosis in human patients in Himachal Pradesh. India. Springerplus. 2014;3:134.
Hedayati MT, Armaki MT, Charati JY, et al. Burden of fungal infections in Iran. J Infect Dev Ctries. 2018;12:910-918.
Ebert A, Monod M, Salamin K, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63:717-728.
Ansari S, Hedayati MT, Zomorodian K, et al. Molecular characterization and in vitro antifungal susceptibility of 316 clinical isolates of dermatophytes in Iran. Mycopathologia. 2016;181:89-95.
Aghamirian MR, Ghiasian SA. Dermatophytoses in outpatients attending the dermatology center of Avicenna Hospital in Qazvin, Iran. Mycoses. 2008;51:155-160.
Naseri A, Fata A, Najafzadeh MJ, Shokri H. Surveillance of dermatophytosis in northeast of Iran (Mashhad) and review of published studies. Mycopathologia. 2013;176:247-253.
Falahati M, Akhlaghi L, Lari AR, Alaghehbandan R. Epidemiology of dermatophytoses in an area south of Tehran, Iran. Mycopathologia. 2003;156:279-287.
Omidynia E, Farshchian M, Sadjjadi M, Zamanian A, Rashidpouraei R. A study of dermatophytoses in Hamadan, the governmentship of West Iran. Mycopathologia. 1996;133:9-13.
Allahdadi M, Hajihossein R, Kord M, Rahmati E, Amanloo S, Didehdar M. Molecular characterization and antifungal susceptibility profile of dermatophytes isolated from scalp dermatophyte carriage in primary school children in Arak city, Center of Iran. J Mycol Med. 2019;29:19-23.
Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, et al. In vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates. Antimicrob Agents Chemother. 2018;62:e02423-17.
Khosravi A, Aghamirian M, Mahmoudi M. Dermatophytoses in Iran: Dermatophytosen in Iran. Mycoses. 1994;37:43-48.
Falahati M, Fateh R, Nasiri A, et al. Specific identification and antifungal susceptibility pattern of clinically important dermatophyte species isolated from patients with dermatophytosis in Tehran, Iran. Arch Clin Infect Dis. 2018;13:e63104.
Thatai P, Sapra B. Critical review on retrospective and prospective changes in antifungal susceptibility testing for dermatophytes. Mycoses. 2016;59:615-627.
Salehi Z, Fatahi N, Izadi A, et al. Comparison of in vitro antifungal activity of novel triazoles with old antifungal agents against dermatophyte species caused tinea pedis. J Mycol Med. 2020;30:100935.
Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477-484.
Taghipour S, Shamsizadeh F, Pchelin IM, et al. Emergence of terbinafine resistant Trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene. Infect Drug Resist. 2020;13:845.
De Hoog GS, Guarro J, Figueras MJ, Gené J. Atlas of clinical fungi. 3rd CD-ROM edn. Utrecht, the Netherlands: CBS-KNAW Fungal Biodiversity Centre; 2009.
White TJ, Bruns T, Lee SJ, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In PCR Protocols: A Guide to Methods and Applications. Cambridge: Academic Press, Inc; 1990;18:315-322.
Espinel-Ingroff A, Canton E. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43:5243-5246.
Wayne P. Clinical and Laboratory Standards Institute (CLSI): Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Carol Stream, IL: Allured Publishing Corporation; 2008.
Gräser Y, Scott J, Summerbell R. The new species concept in dermatophytes-a polyphasic approach. Mycopathologia. 2008;166:239.
Gholami-Shabani M, Shams-Ghahfarokhi M, Shidfar M, Razzaghi-Abyaneh M. Medical mycology in Iran: past, present and future. In: Razzaghi-Abyaneh M, Shams-Ghahfarokhi M, Rai M, eds. Medical Mycology: Current Trends and Future Prospects, 1st edn. Boca Raton, FL: CRC Press (Taylor & Francis Group); 2015:365-417.
Abastabar M, Jedi A, Guillot J, et al. In vitro activities of 15 antifungal drugs against a large collection of clinical isolates of Microsporum canis. Mycoses. 2019;62:1069-1078.
Rezaei-Matehkolaei A, Rafiei A, Makimura K, Gräser Y, Gharghani M, Sadeghi-Nejad B. Epidemiological aspects of dermatophytosis in Khuzestan, southwestern Iran, an update. Mycopathologia. 2016;181:547-553.
Chadeganipour M, Mohammadi R, Shadzi S. A 10-year study of dermatophytoses in Isfahan, Iran. J Clin Lab Anal. 2016;30:103-107.
Maraki S, Mavromanolaki VE. Epidemiology of dermatophytoses in Crete, Greece. Med Mycol J. 2016;57:E69-E75.
Rezaei-Matehkolaei A, Makimura K, de Hoog S, et al. Molecular epidemiology of dermatophytosis in Tehran, Iran, a clinical and microbial survey. Med Mycol. 2013;51:203-207.
Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Eur J Clin. 2018;37:1841-1846.
Bassiri Jahromi S, Khaksar A. Aetiological agents of tinea capitis in Tehran (Iran). Mycoses. 2006;49:65-67.
Waterson L. Education: advancing your practice: fungal infections: Tinea pedis and onychomycosis. Aust J Pharm. 2017;98:90.
Tirado-Sánchez A, Estrada-Caraveo Y, Saldaña M, Bonifaz A. Adult tinea capitis: a clinical entity in increasing frequency. Curr Fungal Infect Rep. 2019;13:196-202.
Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2015;41:374-388.
Iwanaga T, Ushigami T, Anzawa K, Mochizuki T. Viability of pathogenic dermatophytes during a 4-week treatment with 1% topical luliconazole for tinea pedis. Med Mycol J. 2020;58:401-403.
Mistik SE, Ferahbas A, Koc AN, Ayangil D, Ozturk AH. What defines the quality of patient care in tinea pedis? J Eur Acad Dermatol. 2006;20:158-165.
Nouripour-Sisakht S, Mirhendi H, et al. Aspergillus species as emerging causative agents of onychomycosis. J Mycol Med. 2015;25:101-107.
Chadeganipour M, Nilipour S, Ahmadi G. Study of onychomycosis in Isfahan. Iran. Mycoses. 2010;53:153-157.
Baghi N, Shokohi T, Badali H, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol J. 2016;54:757-763.
Javed A, Khajuria V, Tandon VR, Sharma R. Assessment of efficacy of luliconazole cream in management of tinea corporis and tinea cruris infections. J Adv Med Dent Scie Res. 2019;7:48-51.
Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother. 2006;12:163-165.
Ghannoum MA, Long L, Kim HG, Cirino AJ, Miller AR, Mallefet P. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol J. 2010;48:491-497.
Azambuja CV, Pimmel LA, Klafke GB, Xavier MO. Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum. An Bras Dermatol. 2014;89:581-586.
Behnam M, Zarrinfar H, Najafzadeh MJ, Naseri A, Jarahi L, Babič MN. Low in vitro activity of sertaconazole against clinical isolates of dermatophyte. Curr Med Mycol. 2020;6:36.
Deng S, Ansari S, Ilkit M, et al. In vitro antifungal susceptibility profiles of 12 antifungal drugs against 55 Trichophyton schoenleinii isolates from tinea capitis favosa patients in Iran, Turkey, and China. Antimicrob Agents Chemother. 2017;61:e01753-16.
Badali H, Mohammadi R, Mashedi O, de Hoog GS, Meis JF. In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses. 2015;58:303-307.
Dogra S, Shaw D, Rudramurthy SM. Antifungal drug susceptibility testing of dermatophytes: laboratory findings to clinical implications. Indian Dermatol Online J. 2019;10:225.
Chadeganipour M, Nilipour S, Havaei A. In vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan. Mycoses. 2004;47:503-507.
Yenişehirli G, Tunçoğlu E, Yenişehirli A, Bulut Y. In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey. Int J Dermatol. 2013;52:1557-1560.
Sahni K, Singh S, Dogra S. Newer topical treatments in skin and nail dermatophyte infections. Indian Dermatol Online J. 2018;9:149.